+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anticancer Agent"

Injectable Cytotoxic Drugs - Global Strategic Business Report - Product Thumbnail Image

Injectable Cytotoxic Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 380 Pages
  • Global
From
Chemotherapy At-Home Services - Global Strategic Business Report - Product Thumbnail Image

Chemotherapy At-Home Services - Global Strategic Business Report

  • Report
  • February 2026
  • 179 Pages
  • Global
From
From
Marine Pharmaceuticals - Global Strategic Business Report - Product Thumbnail Image

Marine Pharmaceuticals - Global Strategic Business Report

  • Report
  • February 2026
  • 133 Pages
  • Global
From
Antibody Drug Conjugates (ADC) - Global Strategic Business Report - Product Thumbnail Image

Antibody Drug Conjugates (ADC) - Global Strategic Business Report

  • Report
  • February 2026
  • 193 Pages
  • Global
From
Urothelial Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Urothelial Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 126 Pages
  • Global
From
From
From
From
Hepatic Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatic Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Antibody Drug Conjugates - Competitive Landscape, 2026 - Product Thumbnail Image

Antibody Drug Conjugates - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
From
Bispecific Antibodies - Competitive Landscape, 2026 - Product Thumbnail Image

Bispecific Antibodies - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2026 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2026

  • Report
  • January 2026
  • 250 Pages
  • Global
From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
From
FTase (Farnesyltransferase) Inhibitor- Pipeline Insight, 2025 - Product Thumbnail Image

FTase (Farnesyltransferase) Inhibitor- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Proto-oncogene Protein C Mdm2 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Proto-oncogene Protein C Mdm2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Gastric Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Gastric Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 550 Pages
  • Global
From
Loading Indicator

The Anticancer Agent market is a segment of the Healthcare Services industry that focuses on the development and distribution of drugs and treatments for cancer. These agents are designed to target and destroy cancer cells while minimizing the damage to healthy cells. They can be administered orally, intravenously, or topically, depending on the type of cancer and the patient's individual needs. Anticancer agents are used in combination with other treatments such as radiation and chemotherapy to provide the best possible outcome for the patient. The Anticancer Agent market is highly competitive, with many companies vying for market share. Companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more